Opioid Use Disorders

On this page

Opioids 101 - Brain's Poppy Problem

  • Classification:
    • Natural: Morphine, Codeine (from Papaver somniferum)
    • Semi-synthetic: Heroin, Oxycodone, Buprenorphine
    • Synthetic: Fentanyl, Methadone, Pethidine, Tramadol
  • Mechanism of Action (MOA):
    • Agonists at opioid receptors: μ (mu), κ (kappa), δ (delta).
    • Primarily μ-receptor activation: analgesia, euphoria, respiratory depression, miosis.
    • Receptors are G-protein coupled (Gi/Go): ↓ cAMP, open K+ channels (hyperpolarization), close Ca2+ channels (↓ neurotransmitter release).
  • Neurobiology of Addiction:
    • ↑ Dopamine in mesolimbic reward pathway (Ventral Tegmental Area to Nucleus Accumbens).
    • Chronic use leads to neuroadaptation: tolerance & withdrawal. Neurochemical neurocircuits in drug reward

⭐ Buprenorphine is a partial μ-opioid agonist and κ-opioid antagonist, used in opioid de-addiction due to its ceiling effect on respiratory depression and milder withdrawal symptoms compared to full agonists like methadone or heroin. It can precipitate withdrawal if given to a patient on a full μ-agonist due to its high affinity and lower intrinsic activity at the μ-receptor.

OUD Unmasked - Spotting the Signs

  • Opioid Intoxication:
    • Classic Triad: Coma, pinpoint pupils (miosis), respiratory depression.
    • Also: Drowsiness, slurred speech, euphoria, ↓BP, ↓HR.
    • ⚠️ Severe respiratory depression can be fatal.
  • Opioid Withdrawal: (Distressing, rarely life-threatening)
    • Flu-like: Myalgia, fever, lacrimation, rhinorrhea, yawning.
    • GI: Nausea, vomiting, diarrhea, cramps.
    • CNS arousal: Mydriasis, piloerection ("gooseflesh"), insomnia, restlessness, anxiety.
    • Onset: Short-acting (e.g., heroin) 6-12h; Long-acting (e.g., methadone) 24-72h.
    • COWS (Clinical Opiate Withdrawal Scale) for severity.
  • Diagnosis (DSM-5 for OUD):
    • Pattern of use causing significant distress/impairment.
    • Requires ≥2 of 11 criteria over 12 months (impaired control, social impairment, risky use, pharmacological).

    ⭐ Pupil response is a vital diagnostic clue: Miosis (pinpoint) in intoxication, Mydriasis (dilated) in withdrawal.

Crisis Control - Tackling Overdose & Withdrawal

Opioid Overdose

  • Immediate: ABCs (Airway, Breathing, Circulation).
  • Antidote: Naloxone 0.4-2 mg IV/IM/SC; repeat q2-3min.
    • Max 10 mg. No response? Re-evaluate diagnosis.
    • ⚠️ Renarcotization risk (naloxone short half-life).
  • Supportive: O2, ventilation.

Opioid Withdrawal

  • Assess: COWS (Clinical Opiate Withdrawal Scale).
    • Mild: 5-12; Mod: 13-24; Mod-Sev: 25-36; Sev: >36.
  • Symptomatic Rx:
    • Clonidine 0.1-0.3 mg (autonomic; monitor BP).
    • NSAIDs (pain), Loperamide (diarrhea), Ondansetron (N/V).
  • MAT Start: Buprenorphine (COWS >8-12).
    • Day 1: 2-4 mg, up to 8-12 mg.

⭐ Naloxone's short half-life (30-90 min) compared to many opioids (e.g., methadone) necessitates prolonged observation for renarcotization after initial reversal.

Road to Recovery - Long-Term MAT Strategies

  • Methadone:
    • Full µ-opioid agonist.
    • Daily at Opioid Treatment Programs (OTPs).
    • Reduces cravings & withdrawal symptoms.
    • ⚠️ Risk: QTc prolongation, interactions.
  • Buprenorphine:
    • Partial µ-opioid agonist; κ-antagonist.
    • Ceiling effect on respiratory depression.
    • Sublingual (SL), implant, LAI.
    • Often with naloxone to deter IV misuse.
  • Naltrexone:
    • Opioid antagonist; blocks opioid effects.
    • Oral daily or LAI monthly.
    • Requires 7-10 days opioid-free period (precipitated withdrawal risk).
    • Non-addictive, no diversion risk.
  • Psychosocial Support:
    • Essential adjunct (counseling, therapies). OUD Medications and Brain Receptors

⭐ Buprenorphine's availability in office-based settings (unlike methadone for OUD requiring OTPs) improves treatment access.

High‑Yield Points - ⚡ Biggest Takeaways

  • Opioid intoxication triad: miosis (pinpoint pupils), respiratory depression, altered mental status. Antidote: Naloxone.
  • Opioid withdrawal: severe flu-like symptoms (e.g., piloerection, mydriasis, diarrhea, lacrimation), not life-threatening.
  • MAT is first-line: Methadone (long-acting full agonist), Buprenorphine (partial agonist), Naltrexone (antagonist).
  • Buprenorphine can precipitate withdrawal if administered before opioid effects wear off.
  • Naltrexone (oral/injectable) requires full detoxification; contraindicated in acute liver failure.
  • Clonidine helps manage autonomic hyperactivity in withdrawal; Lofexidine is also FDA-approved for this purpose.

Practice Questions: Opioid Use Disorders

Test your understanding with these related questions

A patient presents to the emergency department with vomiting, diarrhea, lacrimation, abdominal cramps, and piloerection. The family members report a history of substance use for the past month. The clinical presentation is due to what?

1 of 5

Flashcards: Opioid Use Disorders

1/1

A patient of delirium tremens will have features of _____kalemia, hypomagenesemia, hypovolemia and hypophosphatemia

TAP TO REVEAL ANSWER

A patient of delirium tremens will have features of _____kalemia, hypomagenesemia, hypovolemia and hypophosphatemia

hypo

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial